In the world of cancer drugs, calling a new entry "the next Avastin" or "the next Gleevec" is like picking out the next Brad Pitt or the next Beyoncé. Those two treatments were among a crop of future blockbusters launched as the new millennium kicked into gear, and they're top sellers today. But that's just what the IMS Institute for Healthcare Informatics is doing in its latest report on the pharma business. Report